Plain-English translation of NCT07000916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term research study that tracks young people (age 50 and under) who have been recently diagnosed with arthritis or related autoimmune conditions like lupus or scleroderma. Doctors want to understand how well standard treatments work, which patients do best, and how to help more people reach remission — meaning their disease is under control or goes away.
Right now, doctors don't always follow new arthritis patients the same way, and we don't have clear answers about which patients will respond best to treatment or achieve remission. This study aims to create better, more consistent care guidelines so that younger people diagnosed with these conditions get the best possible outcomes.
You likely qualify if…
You likely don't qualify if…
You would join one of five groups based on your specific diagnosis. Over 5 to 10 years, you would have regular clinic visits where doctors monitor how your disease responds to treatment, check your quality of life, and run standardized tests to measure whether your condition is under control or in remission. The study aims to enroll about 1,000 patients across three French-speaking universities, with special focus on newly diagnosed cases.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Belgium
Sponsor
Université Catholique de Louvain
Enrollment target
~1,000 participants
Started
September 2013
Primary completion
March 2028
Age range
2 Years – 50 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Patrick Durez
UCLouvain - IREC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.